EG25822A - Quinolinyl-pyrrolopyrazoles - Google Patents
Quinolinyl-pyrrolopyrazolesInfo
- Publication number
- EG25822A EG25822A EGNA2005000237A EG25822A EG 25822 A EG25822 A EG 25822A EG NA2005000237 A EGNA2005000237 A EG NA2005000237A EG 25822 A EG25822 A EG 25822A
- Authority
- EG
- Egypt
- Prior art keywords
- pyrrolopyrazoles
- quinolinyl
- compound
- administration
- patient
- Prior art date
Links
- RAFDNHHMCKZGCT-UHFFFAOYSA-N 2-pyrrolo[3,2-c]pyrazol-3-ylquinoline Chemical class C1=CC=CC2=NC(C3=C4N=CC=C4N=N3)=CC=C21 RAFDNHHMCKZGCT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42889302P | 2002-11-22 | 2002-11-22 | |
| PCT/US2003/032747 WO2004048382A1 (en) | 2002-11-22 | 2003-11-10 | Quinolinyl-pyrrolopyrazoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EG25822A true EG25822A (en) | 2012-08-23 |
Family
ID=32393478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EGNA2005000237 EG25822A (en) | 2002-11-22 | 2005-05-18 | Quinolinyl-pyrrolopyrazoles |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7265225B2 (enExample) |
| EP (1) | EP1565471B1 (enExample) |
| JP (1) | JP4542906B2 (enExample) |
| KR (1) | KR101057282B1 (enExample) |
| CN (1) | CN100345852C (enExample) |
| AT (1) | ATE341550T1 (enExample) |
| AU (1) | AU2003291643B2 (enExample) |
| BR (1) | BR0315337A (enExample) |
| CA (1) | CA2501322C (enExample) |
| CO (1) | CO5570677A2 (enExample) |
| CR (1) | CR7830A (enExample) |
| CY (1) | CY1106283T1 (enExample) |
| DE (1) | DE60308893T2 (enExample) |
| DK (1) | DK1565471T3 (enExample) |
| EA (1) | EA008387B1 (enExample) |
| EC (1) | ECSP055807A (enExample) |
| EG (1) | EG25822A (enExample) |
| ES (1) | ES2273046T3 (enExample) |
| HR (1) | HRP20050436B1 (enExample) |
| IL (1) | IL168190A (enExample) |
| MX (1) | MXPA05005432A (enExample) |
| NO (1) | NO331403B1 (enExample) |
| NZ (1) | NZ538942A (enExample) |
| PL (1) | PL227840B1 (enExample) |
| PT (1) | PT1565471E (enExample) |
| UA (1) | UA80571C2 (enExample) |
| WO (1) | WO2004048382A1 (enExample) |
| ZA (1) | ZA200503121B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| EP1567527A1 (en) * | 2002-11-27 | 2005-08-31 | Eli Lilly And Company | Condensed pyrazolo derivatives |
| MX2008001020A (es) | 2005-07-22 | 2008-03-25 | Lilly Co Eli | Un monohidrato de pirrolo[1-2-b]pirazol piridin quinolin substituido como inhibidor de factor de crecimiento de transformacion-beta (tgf-beta). |
| WO2007039151A1 (en) * | 2005-09-28 | 2007-04-12 | Universität Zürich | Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases |
| WO2008060371A1 (en) | 2006-10-03 | 2008-05-22 | Genzyme Corporation | USE OF TGF-β ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA |
| ES2435430T3 (es) * | 2006-10-16 | 2013-12-19 | Thesan Pharmaceuticals, Inc. | Pirazolil tienopiridinas terapéuticas |
| US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| PE20141066A1 (es) | 2011-04-21 | 2014-09-05 | Gilead Sciences Inc | Compuestos de benzotiazol |
| EP2737083A1 (en) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Methods for diagnosing and treating myhre syndrome |
| BR112014009789A2 (pt) | 2011-10-26 | 2017-04-25 | Seattle Children's Res Inst | cisteamina no tratamento da doença fibrótica |
| US9782452B2 (en) | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| PH12014500842A1 (en) | 2012-04-20 | 2014-06-09 | Gilead Sciences Inc | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection |
| WO2014055998A1 (en) | 2012-10-05 | 2014-04-10 | Kadmon Corporation, Llc | Human anti-vegfr-2/kdr antibodies |
| ES2791627T3 (es) | 2012-11-12 | 2020-11-05 | Inst Catalana Recerca Estudis Avancats | Métodos y kits para el pronóstico del cáncer colorrectal |
| TWI582083B (zh) | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| ES2918924T3 (es) | 2015-04-01 | 2022-07-21 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
| US10450318B2 (en) | 2015-12-15 | 2019-10-22 | Bristol-Myers Squibb Company | CXCR4 receptor antagonists |
| WO2018006870A1 (zh) * | 2016-07-07 | 2018-01-11 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| US11111248B2 (en) | 2017-03-17 | 2021-09-07 | Hangzhou Solipharma Co., Ltd. | Crystal form of 2-(6-methyl-pyridin-2-yl)-3-yl-[6-amido-quinolin-4-yl]-5,6-dihydro-4H-pyrrolo[1,2-B]pyrazole, preparation method therefor and pharmaceutical composition thereof |
| CN110582279B (zh) * | 2017-03-21 | 2023-07-14 | 杭州领业医药科技有限公司 | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物 |
| WO2019042383A1 (zh) * | 2017-08-31 | 2019-03-07 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019105082A1 (zh) * | 2017-11-30 | 2019-06-06 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019137027A1 (zh) * | 2018-01-12 | 2019-07-18 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| EP3827010B1 (en) | 2018-07-23 | 2025-08-27 | Brise Pharmaceuticals Co., Ltd. | Bisphosphonate drug conjugates |
| CN113348167A (zh) | 2018-12-27 | 2021-09-03 | 奈可萨斯医药有限公司 | 用于治疗癌症的作为TGF-βR1(ALK5)抑制剂的(吡啶-2-基)胺衍生物 |
| EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| WO2020248908A1 (zh) * | 2019-06-10 | 2020-12-17 | 中国科学院广州生物医药与健康研究院 | 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 |
| JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| AU2021223336A1 (en) | 2020-02-19 | 2022-10-06 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereof |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| GB202309553D0 (en) | 2023-06-24 | 2023-08-09 | Ucl Business Ltd | Compostions and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| EP1206474B1 (en) * | 1999-08-27 | 2004-05-26 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| ES2289116T3 (es) | 2001-05-24 | 2008-02-01 | Eli Lilly And Company | Nuevos derivados de pirrol como agentes farmaceuticos. |
| EP1567528A1 (en) | 2002-11-21 | 2005-08-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
-
2003
- 2003-10-11 UA UAA200504767A patent/UA80571C2/uk unknown
- 2003-11-10 US US10/531,237 patent/US7265225B2/en not_active Expired - Fee Related
- 2003-11-10 MX MXPA05005432A patent/MXPA05005432A/es active IP Right Grant
- 2003-11-10 CN CNB2003801038400A patent/CN100345852C/zh not_active Expired - Fee Related
- 2003-11-10 KR KR1020057009199A patent/KR101057282B1/ko not_active Expired - Fee Related
- 2003-11-10 NZ NZ538942A patent/NZ538942A/en not_active IP Right Cessation
- 2003-11-10 ES ES03768531T patent/ES2273046T3/es not_active Expired - Lifetime
- 2003-11-10 AT AT03768531T patent/ATE341550T1/de active
- 2003-11-10 CA CA2501322A patent/CA2501322C/en not_active Expired - Fee Related
- 2003-11-10 DE DE60308893T patent/DE60308893T2/de not_active Expired - Lifetime
- 2003-11-10 PT PT03768531T patent/PT1565471E/pt unknown
- 2003-11-10 AU AU2003291643A patent/AU2003291643B2/en not_active Ceased
- 2003-11-10 HR HRP20050436AA patent/HRP20050436B1/hr not_active IP Right Cessation
- 2003-11-10 EP EP03768531A patent/EP1565471B1/en not_active Expired - Lifetime
- 2003-11-10 DK DK03768531T patent/DK1565471T3/da active
- 2003-11-10 PL PL376797A patent/PL227840B1/pl unknown
- 2003-11-10 EA EA200500859A patent/EA008387B1/ru not_active IP Right Cessation
- 2003-11-10 JP JP2004555329A patent/JP4542906B2/ja not_active Expired - Fee Related
- 2003-11-10 WO PCT/US2003/032747 patent/WO2004048382A1/en not_active Ceased
- 2003-11-10 BR BR0315337-1A patent/BR0315337A/pt not_active Application Discontinuation
-
2005
- 2005-04-18 ZA ZA200503121A patent/ZA200503121B/en unknown
- 2005-04-21 IL IL168190A patent/IL168190A/en active IP Right Grant
- 2005-05-06 CR CR7830A patent/CR7830A/es unknown
- 2005-05-18 EG EGNA2005000237 patent/EG25822A/xx active
- 2005-05-18 CO CO05048136A patent/CO5570677A2/es active IP Right Grant
- 2005-05-19 EC EC2005005807A patent/ECSP055807A/es unknown
- 2005-06-21 NO NO20053045A patent/NO331403B1/no not_active IP Right Cessation
-
2006
- 2006-12-08 CY CY20061101769T patent/CY1106283T1/el unknown
-
2007
- 2007-07-25 US US11/782,659 patent/US7834029B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG25822A (en) | Quinolinyl-pyrrolopyrazoles | |
| TNSN06032A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
| WO2004045523A3 (en) | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | |
| SG2013013339A (en) | N3 alkylated benzimidazole derivatives as mek inhibitors | |
| WO2005011655A3 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| TW200638935A (en) | Pyridazine derivatives and their use as therapeutic agents | |
| WO2005023759A3 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| GB0130677D0 (en) | Medicaments and novel compounds | |
| UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors | |
| DK1689404T3 (da) | Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer | |
| TW200508199A (en) | Novel compound | |
| NO20003313L (no) | Terapeutiske midler | |
| MY133107A (en) | Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia | |
| SE9900070D0 (sv) | New use | |
| MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
| NO20031410D0 (no) | Antitumorterapi innbefattende distamycinderivater | |
| PL1648473T3 (pl) | Pojedyncza dawka szybko rozpuszczającej się azytromycyny | |
| MXPA01012936A (es) | Composicion farmaceutica que contiene sibutramina y orlistat. | |
| MXPA05011418A (es) | Metodo para administracion de troxacitabina. | |
| YU30602A (sh) | Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima | |
| CY1109852T1 (el) | Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη | |
| EP1347754A4 (en) | COMPOSITIONS FOR PREVENTION OF ADHESION | |
| AU2002211217A1 (en) | Method of treating stroke | |
| JO2829B1 (en) | Pyridazine derivatives and their use as therapeutic agents |